NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Holdings Boosted by DCF Advisers LLC

Key Points

• DCF Advisers LLC increased its stake in NewAmsterdam Pharma by 93.0%, acquiring an additional 83,100 shares, which makes the stock approximately 1.7% of their total holdings.
• Several institutional investors significantly boosted their positions in NewAmsterdam Pharma, with Wellington Management Group increasing its holdings by 2,410.4% during the fourth quarter.
• Analysts from multiple firms have issued a consensus rating of Moderate Buy for NewAmsterdam Pharma, with a price target averaging $41.30.

DCF Advisers LLC raised its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 93.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 172,500 shares of the company's stock after purchasing an additional 83,100 shares during the quarter. NewAmsterdam Pharma makes up 1.7% of DCF Advisers LLC's holdings, making the stock its 17th biggest position. DCF Advisers LLC owned about 0.16% of NewAmsterdam Pharma worth $3,531,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at about $50,000. National Bank of Canada FI acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in NewAmsterdam Pharma by 19.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after purchasing an additional 596 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after purchasing an additional 3,390 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in NewAmsterdam Pharma in the 1st quarter valued at approximately $127,000. Institutional investors own 89.89% of the company's stock.

Insider Buying and Selling

In other NewAmsterdam Pharma news, COO Douglas F. Kling sold 51,043 shares of the business's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $21.10, for a total value of $1,077,007.30. Following the sale, the chief operating officer owned 44,000 shares in the company, valued at $928,400. The trade was a 53.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James N. Topper bought 2,520 shares of the stock in a transaction on Tuesday, June 24th. The stock was purchased at an average price of $18.43 per share, with a total value of $46,443.60. Following the completion of the purchase, the director owned 3,024,873 shares of the company's stock, valued at $55,748,409.39. This represents a 0.08% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 12,364 shares of company stock valued at $236,839 and have sold 198,612 shares valued at $4,025,887. Company insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock traded down $0.95 on Thursday, hitting $22.68. 110,990 shares of the stock traded hands, compared to its average volume of 869,141. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $27.29. The company has a market capitalization of $2.55 billion, a PE ratio of -12.08 and a beta of -0.02. The company's fifty day moving average is $20.48 and its 200 day moving average is $20.02.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The firm had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. As a group, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Analyst Ratings Changes

NAMS has been the subject of a number of research reports. Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 target price for the company. Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Stifel Nicolaus began coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price objective for the company. The Goldman Sachs Group initiated coverage on shares of NewAmsterdam Pharma in a research note on Thursday, July 17th. They set a "neutral" rating and a $27.00 target price on the stock. Finally, Citigroup initiated coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a "buy" rating and a $42.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $41.20.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.